Bexon Clinical Consulting (United States)

Recent papers from Bexon Clinical Consulting (United States)

1. Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid TumorsCancer Research Communications · 2026
2. The role of the microbiome in gynecological cancers: implications for diagnosis and treatmentSHILAP Revista de lepidopterología · 2026
3. Abstract CT052: Proof of mechanism from a phase 1, single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LRK-4189 in healthy subjectsCancer Research · 2026
4. Abstract CT118: Clinical pharmacokinetic and pharmacodynamic of JBZ-001 (HOSU-53): Comparison of first-in-human data with translational preclinical predictionsCancer Research · 2026
5. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumorsJournal for ImmunoTherapy of Cancer · 2025
6. Ontology enrichment using a large language model: Applying lexical, semantic, and knowledge network-based similarity for concept placementJournal of Biomedical Informatics · 2025
7. CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trialEClinicalMedicine · 2024
8. First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE).Journal of Clinical Oncology · 2024
9. Phase 2 study to evaluate the novel mitochondrial PRX3 inhibitor, RSO-021, as an intrapleural monotherapy and in combination with IV paclitaxel in patients with malignant pleural effusion due to mesothelioma or another advanced solid tumor.Journal of Clinical Oncology · 2024
10. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialNature Medicine · 2023
11. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activationFrontiers in Immunology · 2022
12. 958 BNT211: a phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and vaccine-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumorsBMJ · 2021
13. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans2020
14. Concurrent human antibody and T H 1 type T-cell responses elicited by a COVID-19 RNA vaccine2020
15. Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on HepatotoxicityDrug Safety · 2020
16. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancersPLoS ONE · 2018